NCT00413660

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

A Phase 2B, Randomized, Double Blind, Placebo-Controlled, Multicenter Study To Compare 6 Dose Regimens Of CP-690,550 Vs. Placebo, Each Combined With Methotrexate, Administered For 6 Months In The Treatment Of Subjects With Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate Alone

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 509 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	CP-690,550	4 blinded tablets administered BID
DRUG	CP-690,550	4 blinded tablets administered BID
DRUG	CP-690,550	4 blinded tablets administered BID
DRUG	CP-690,550	4 blinded tablets administered BID
DRUG	CP-690,550	4 blinded tablets administered BID
DRUG	CP-690,550	Oral tablets
OTHER	placebo	Placebo

Timeline

• Start date: 2007-01-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2006-12-20
• Last updated: 2013-01-18
• Results posted: 2013-01-08

Locations

82 sites across 13 countries: United States, Argentina, Brazil, Bulgaria, Chile, Czechia, Hungary, Mexico, Poland, Slovakia, Spain, Sweden, Turkey (Türkiye)